Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-recordati-rare-diseases-pedea-5-mg-slash-ml-solution-for-injection-el-22-a-slash-45
https://www.businesswire.com/news/home/20210323005021/en/Recordati-Rare-Diseases-Positive-Results-From-the-Phase-III-LINC-4-Study-Presented-Today-at-the-Endocrine-Society%E2%80%99s-Annual-Meeting-Reinforce-the-Efficacy-and-Safety-of-Isturisa%C2%AE-osilodrostat-in-Cushing%E2%80%99s-Disease
https://www.biospace.com/article/releases/recordati-rare-diseases-announces-availability-of-cystadrops-cysteamine-ophthalmic-solution-0-37-percent-in-the-u-s-/
https://www.prnewswire.com/news-releases/us-fda-approves-cystadrops-cysteamine-ophthalmic-solution-0-37-a-new-practical-treatment-option-for-the-ocular-manifestations-of-cystinosis-301118026.html
https://www.fiercepharma.com/pharma/cvc-aims-for-rare-disease-leadership-3-5b-recordati-buy